Medical News

RSS

New training programs help ease serious staffing crisis in hospital laboratory

Imagine needing a critical test at your local hospital, but having to wait days to be tested because there was no laboratory professional available to run the tests. This scene seems unimaginable, but with the federal government estimating that nearly 140,000 new medical lab professionals are needed by 2012 and only 50,000 are expected to be trained on time, this scenario is a reality in some parts of the country. Some states, like California, are taking aggressive action to reverse this trend.

29 Jul 2010

Partnership for Safe Medicines to convene counterfeit drug conference

The Partnership for Safe Medicines (PSM), a group of nonprofit organizations and individuals dedicated to protecting consumers from counterfeit drugs, today announced that it will convene leaders from academia, government and industry in an inaugural conference to be held October 8th at the National Press Club in Washington, D.C.

29 Jul 2010

The Children's Hospital constructs new LEED-certified patient tower

The Children's Hospital has begun the construction of a 10-story, 350,000-square-foot addition. The $230 million expansion of a new patient tower initially will have 124 beds, with two floors of shelled space for additional future beds, bringing the total number of patient beds at Children's to around 500 upon full completion. The expansion also is expected to bring approximately 500 new jobs to the hospital's workforce. Children's anticipates admitting patients in the LEED-certified tower beginning in late 2012.

29 Jul 2010

Nymox provides update on NX-1207 Phase 3 program for benign prostatic hyperplasia

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia (BPH). The Safety Monitoring Committee meeting of July 22, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 was favorable and indicated no significant safety concerns for the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 70 well-known urology investigative sites throughout the U.S.

29 Jul 2010

Research to help people born with 'face blindness'

A specific area in our brains is responsible for processing information about human and animal faces, both how we recognize them and how we interpret facial expressions. Now, Tel Aviv University research is exploring what makes this highly specialized part of the brain unique, a first step to finding practical applications for that information.

29 Jul 2010

Researchers to evaluate effect of RTC program on patient outcomes

Researchers at the Health Quality Council and the University of Saskatchewan will be the first to rigorously evaluate a quality improvement program designed to help nurses and other care providers reduce the time they spend on administrative tasks or retrieving medical supplies, so that they can spend more time with their patients.

29 Jul 2010

FAO launches initiative to curb animal diseases

In an effort to prevent and control outbreaks of animal diseases and the associated costs, the U.N. Food and Agriculture Organization on Monday announced a new five-year initiative "to improve global response to disease outbreaks, implement effective prevention and containment strategies and manage risks," PANA/Afrique en ligne reports (7/28).

29 Jul 2010

PacificHealth Laboratories second-quarter revenues decrease to $2.55 million

PacificHealth Laboratories, Inc., a leading sports nutrition company, today reported its financial results for the quarter and six months ended June 30, 2010.

29 Jul 2010

Scientists develop new version of medication to relieve severe forms of pain

Scientists have developed a new version of a medication, first isolated from the saliva of sea snails, that could be taken in pill form to relieve the most severe forms of pain as effectively as morphine but without risking addiction. An article on the topic appears in the current issue of Chemical & Engineering News, ACS' weekly newsmagazine.

29 Jul 2010

Advaxis provides update on survival information from ADXS11-001 phase 1 trial in cervix cancer

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy.

29 Jul 2010

PCMA issues statement on a provision in the U.S. Senate's small business legislation

Pharmaceutical Care Management Association President and CEO Mark Merritt issued the following statement today on a provision in the U.S. Senate's small business legislation that would require the Department of Health and Human Services to work with outside companies to target fraud, waste, and abuse in states across the country.

29 Jul 2010

Reliance on assistive devices can affect everyday life in multiple ways: Study

Obese older adults are more likely to use walkers, canes and other mobility devices at a younger age, and may run the risk of using them incorrectly, according to new research from Purdue University.

29 Jul 2010

Oxford Finance leads $30 million credit facility provided to Cadence for launch of OFIRMEV

Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, today announced that it was the lead lender for a $30 million credit facility provided to Cadence Pharmaceuticals. Silicon Valley Bank and GE Financial Services, Inc. also participated in the loan agreement. This infusion of capital will support the company's potential launch of their investigational product candidate, OFIRMEV™, an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever.

29 Jul 2010

Oxford Life Insurance releases new Medicare Supplement product portfolio

Oxford Life Insurance Company today announced the release of its new Medicare Supplement product portfolio. The Phoenix-based life insurance company has plans to market Plans A, C or F, and N in more than 35 states.

29 Jul 2010

Texas raises organ donor registry; D.C. not ready for medical marijuana sales; L.A. health department facing major service cuts

"Though Texas has the nation's lowest percentage of registered organ and tissue donors, several recent initiatives have more than doubled the state's donor rolls this year. The number enrolled in the Glenda Dawson Donate Life Texas Registry has ballooned since Jan. 1, when state law required Department of Public Safety clerks to ask all driver's license and ID card applicants whether they would like to register as organ donors. Since then, nearly 70,000 donors a month have joined the pool" (George, 7/27).

29 Jul 2010

Advanced Protein Systems is now APS BioGroup

APS BioGroup, formerly Advanced Protein Systems, the world's largest producer of colostrum products, announces its new company name and expanded focus to include advancements in private label contract manufacturing for health supplements and the introduction of Immulox®, an immune support product and supplement ingredient derived from colostrum.

29 Jul 2010

Noveko RD2 antimicrobial respirators obtain FFP2 classification

Noveko International Inc. is pleased to announce that its subsidiary Noveko Inc. has obtained FFP2 classification for its new model of antimicrobial respirators and can now bring them to market in all countries throughout the European Union. These respirators will be marketed as Noveko RD2 antimicrobial respirators.

29 Jul 2010

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Dendreon Corporation announced today the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer. The manuscript is published in the July 29, 2010 issue of the journal.

29 Jul 2010

Merit Medical second-quarter revenues increase 16% to $74.9 million

Merit Medical Systems, Inc., a leading manufacturer and marketer of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and gastroenterology, today announced record revenues of $74.9 million for the quarter ended June 30, 2010, an increase of 16% over revenues of $64.8 million for the quarter ended June 30, 2009. Revenues for the six-month period ended June 30, 2010 were a record $142.4 million, compared with $123.2 million for the corresponding period in 2009, a gain of 16%.

29 Jul 2010

Researchers unveil mechanism of cholera bacteria to create cell energy

Researchers have found that an enzyme in the bacteria that causes cholera uses a previously unknown mechanism in providing the bacteria with energy. Because the enzyme is not found in most other organisms, including humans, the finding offers insights into how drugs might be created to kill the bacteria without harming humans.

29 Jul 2010